Abstract
Myasthenic crisis is a serious occurrence, affecting up to 27% of patients with myasthenia gravis. In the approach to the patient with myasthenic crisis, (1) the diagnosis of myasthenia gravis is confirmed; (2) respiratory failure is evaluated and treated in the intensive care unit, while potential precipitating factors are identified and managed; (3) immunomodulatory treatment is initiated; and (4) complications are avoided or managed promptly. The mortality rate should be 5% or less, with the elderly being most vulnerable.
Similar content being viewed by others
References
Berrouschot J, Baumann I, Kalischewski P, Sterker M, Schneider D. Therapy of myasthenic crisis. Crit Care Med 1997;25:1228–1235.
Cohen MS, Younger D. Aspects of the natural history of myasthenia gravis: crisis and death. Ann NY Acad Sci 1981;377:670–677.
Oosterhuis HJ. Observations of the natural history of myasthenia gravis and the effect of thymectomy. Ann NY Acad Sci 1981;377:678–690.
Thomas CE, Mayer SA, Gungor Y, et al. Myasthenic crisis: clinical features, mortality, complications, and risk factors for prolonged intubation. Neurology 1997;48:1253–1260.
Varelas PN, Chua HC, Natterman J, et al. Ventilatory care in myasthenia gravis crisis: assessing the baseline adverse event rate. Crit Care Med 2002;30:2663–2668.
Bedlack RS, Sanders DB. On the concept of myasthenic crisis. J Clin Neuromuscul Dis 2002;4:40–42.
Keesey JC. “Crisis” in myasthenia gravis: an historical perspective. Muscle Nerve 2002;26:1–3.
Oh SJ, Kim DE, Kuruoglu R, Bradley RJ, Dwyer D. Diagnostic sensitivity of the laboratory tests in myasthenia gravis. Muscle Nerve 1992;15:720–724.
Zifko UA, Nicolle MW, Grisold W, Bolton CF. Repetitive phrenic nerve stimulation in myasthenia gravis. Neurology 1999;53:1083–1087.
Limburg PC, The TH, Hummel-Tappel E, Oosterhuis HJ. Antiacetylcholine receptor antibodies in myasthenia gravis. Part 1. Relation to clinical parameters in 250 patients. J Neurol Sci 1983;58:357–370.
Evoli A, Tonali PA, Padua L, et al. Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis. Brain 2003;126:2304–2311.
Bedlack RS, Sanders DB. How to handle myasthenic crisis. Essential steps in patient care. Postgrad Med 2000;107:211–214, 220–222.
Bucknall RC, Dixon A St J, Glick EN, Woodland J, Zutshi DW. Myasthenia gravis associated with penicillamine treatment for rheumatoid arthritis. Br Med J 1975;1:600–602.
Lensch E, Faust J, Nix WA, Wandel E. Myasthenia gravis after interferon-α treatment. Muscle Nerve 1996;19:927–928.
Pascuzzi RM. Medications and myasthenia gravis. Myasthenia Gravis Foundation of America, Inc. 2004. http://www.myasthenia.org/drugs.
Drachman DA, Skom JH. Procainamide-a hazard in myasthenia gravis. Arch Neurol 1965;13:316–320.
Herishanu Y, Rosenberg P. β-Blockers and myasthenia gravis. Ann Intern Med 1975;83:834–835.
Miller RD, Way WL, Katzung BG. The neuromuscular effects of quinidine. Proc Soc Exp Biol Med 1968;129:215–217.
Moore B, Safani M, Keesey J. Possible exacerbation of myasthenia gravis by ciprofloxacin. Lancet 1988;1:882.
Ribera AB, Nastuk WL. The actions and verapamil at the neuromuscular junction. Comp Biochem Physiol C Toxicol Pharmacol 1989;93:137–141.
Torda T. The nature of gentamicin-induced neuromuscular block. Br J Anaesth 1980;52:325–329.
Eliashiv S, Wirguin I, Brenner T, Argov Z. Aggravation of human and experimental myasthenia gravis by contrast media. Neurology 1990;40:1623–1625.
Argov Z, Brenner T, Abramsky O. Ampicillin may aggravate clinical and experimental myasthenia gravis. Arch Neurol 1986;43:255–256.
Brumlik J, Jacobs RS. Myasthenia gravis associated with diphenylhydantoin therapy for epilepsy. Can J Neurol Sci 1974;1:127–129.
Pittinger C, Adamson R. Antibiotic blockade of neuromuscular function. Annu Rev Pharmacol 1972;12:169–184.
Watanabe A, Watanabe T, Obama T, Mawatari T, Ohsawa H, Ichimiya Y, et al. Prognostic factors for myasthenic crisis after transsternal thymectomy in patients with myasthenia gravis. J Thorac Cardiovasc Surg 2004;127:868–876.
Rabinstein AA, Wijdicks EF. Warning signs of imminent respiratory failure in neurologic patients. Semin Neurol 2003;23:97–104.
Fitting J-W, Paillex R, Hirt L, Aebischer P, Schluep M. Sniff nasal pressure: a sensitive respiratory test to assess progression of amyotrophic lateral sclerosis. Ann Neurol 1999;46:887–893.
Rieder P, Louis M, Jolliet P, Chevrolet J-C. The repeated measurement of vital capacity is a poor predictor of the need for mechanical ventilation in myasthenia gravis. Intensive Care Med 1995;21:663–668.
Rabinstein A, Wijdicks EF. BiPAP in acute respiratory failure due to myasthenic crisis may prevent intubation. Neurology 2002;59:1647–1649.
Fink ME. Treatment of the critically ill patient with myasthenia gravis. In: Ropper AH, ed. Neurological and neurosurgical intensive care, 3rd ed. Raven, New York, 1993.
Mayer SA, Thomas CE. Therapy of myasthenic crisis. Crit Care Med 1998;26:1136–1137.
Esteban A, Frutos-Vivar F, Ferguson ND, et al. Noninvasive positive-pressure ventilation for respiratory failure after extubation. N Engl J Med 2004;350:2452–2460.
Qureshi AI, Choudhry MA, Akbar MS, et al. Plasma exchange versus intravenous immunoglobulin treatment in myasthenic crisis. Neurology 1999;52:629–632.
Panegyres PK, Squier M, Mills KR, Newsom-Davis J. Acute myopathy associated with large parenteral dose of corticosteroid in myasthenia gravis. J Neurol Neurosurg Psychiatry 1993;56:702–704.
Drachman DB. Myasthenia gravis. N Engl J Med 1994;330:1797–1810.
Guglin M, Campbellone JV, Heintz K, Parrillo JE. Cardiac disease in myasthenia gravis. J Clin Neuromusc Dis 2003;4:199–203.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Lacomis, D. Myasthenic crisis. Neurocrit Care 3, 189–194 (2005). https://doi.org/10.1385/NCC:3:3:189
Issue Date:
DOI: https://doi.org/10.1385/NCC:3:3:189